Sitagliptin Phosphate Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 25 mg, 50 mg, 100 mg
Reference Brands: Januvia(US & EU)
Category:
Diabetes
Sitagliptin is a DPP-4 inhibitor that enhances incretin levels, increasing insulin release and decreasing glucagon secretion in a glucose-dependent manner. This improves glycemic control without causing hypoglycemia. It’s weight-neutral, well-tolerated, and effective as monotherapy or in combination therapy for Type 2 diabetes, supporting long-term blood sugar regulation.
Sitagliptin Phosphate Tablets is available in Tablets
and strengths such as 25 mg, 50 mg, 100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Sitagliptin Phosphate Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Sitagliptin Phosphate Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Sitagliptin, marketed under the brand name Januvia, is a DPP-4 inhibitor approved for managing type 2 diabetes mellitus. In the USA, the FDA approved Sitagliptin in 2006, and it remains under brand protection with limited generic availability. In the EU, it received EMA approval in 2007 and is available in multiple strengths (25 mg, 50 mg, 100 mg). Sitagliptin is used as monotherapy or in combination with other antidiabetic agents. Pharmacovigilance data confirms a favorable safety profile. With patent expirations approaching in some regions, generic versions are beginning to enter select EU markets. Widely sourced via platforms like Pharmatradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing